PD-L1 expression in extrahepatic cholangiocarcinoma

Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma

(2016) Faiz Gani et al.   ANNALS OF SURGICAL ONCOLOGY

Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma

(2015) J. Bellmunt et al.   ANNALS OF ONCOLOGY

PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma

(2015) F. Sabbatino et al.   CLINICAL CANCER RESEARCH

PD-L1 expression in small cell neuroendocrine carcinomas

(2015) Anne M. Schultheis et al.   EUROPEAN JOURNAL OF CANCER

Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers

(2015) Moon-Young Kim et al.   LUNG CANCER

Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma

(2015) Yuki Katsuya et al.   LUNG CANCER

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

(2015) S. P. Patel et al.   MOLECULAR CANCER THERAPEUTICS

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies

(2015) Giovanni Brandi et al.   Oncotarget

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma

(2015) Silvia Darb-Esfahani et al.   Oncotarget

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

(2014) S. Muenst et al.   BREAST CANCER RESEARCH AND TREATMENT

Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy

(2014) Yuichiroh Umemoto et al.   JOURNAL OF GASTROENTEROLOGY

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

(2012) Suzanne L Topalian et al.   CURRENT OPINION IN IMMUNOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma

(2010) Horlad Hasita et al.   CANCER SCIENCE

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

(2009) M. Ahmadzadeh et al.   BLOOD

Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion

(2009) Yufu Ye et al.   JOURNAL OF SURGICAL ONCOLOGY